Sexually Transmitted Diseases

Skip Navigation LinksHome > February 2003 - Volume 30 - Issue 2 > The Clinical and Economic Consequences of Screening Young Me...
Text sizing:
A
A
A
Sexually Transmitted Diseases:
Article

The Clinical and Economic Consequences of Screening Young Men for Genital Chlamydial Infection

GINOCCHIO, RACHEL H. S. MPH*; VEENSTRA, DAVID L. PharmD, PhD†; CONNELL, FREDERICK A. MD, MPH*; MARRAZZO, JEANNE M. MD, MPH‡

Collapse Box

Abstract

Background: Wide-scale application of urine-based screening of asymptomatic men for chlamydial infection has not been thoroughly assessed.

Goal: The goal was to compare clinical and economic consequences of three strategies: (1) no screening, (2) screening with ligase chain reaction (LCR) assay of urine, and (3) prescreening urine with a leukocyte esterase test (LE) and confirming positives with LCR.

Study Design: We used a decision analytic model.

Results: At a chlamydia prevalence of 5%, the no screening cost was $7.44 per man screened, resulting in 522 cases of pelvic inflammatory disease (PID) per 100,000 men. LE-LCR was most cost-effective, preventing 242 cases of PID over no screening at an additional cost of $29.14 per male screened. The LCR strategy prevented 104 more cases of PID than LE-LCR but cost $22.62 more per male screened. For this to be more efficient than LE-LCR, the LCR assay cost needed to decline to ≤$18.

Conclusion: At a chlamydia prevalence of 5%, LE-LCR is the most efficient use of resources. If LCR cost decreases or chlamydia prevalence increases, the LCR strategy is favored.

© Copyright 2003 American Sexually Transmitted Diseases Association

Login

Article Tools

Share

Article Level Metrics